LAVA Therapeutics N.V. (LVTX)
NASDAQ: LVTX · IEX Real-Time Price · USD
3.030
-0.070 (-2.26%)
At close: May 3, 2024, 4:00 PM
2.950
-0.080 (-2.64%)
After-hours: May 3, 2024, 5:55 PM EDT
LAVA Therapeutics Revenue
In the year 2023, LAVA Therapeutics had annual revenue of $7.52M, a decrease of -63.54%. Revenue in the quarter ending December 31, 2023 was $392.22K, a -86.03% decrease year-over-year.
Revenue (ttm)
$7.52M
Revenue Growth
-63.54%
P/S Ratio
10.59
Revenue / Employee
$203,273
Employees
37
Market Cap
79.66M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7.52M | -13.11M | -63.54% |
Dec 31, 2022 | 20.63M | 14.55M | 239.31% |
Dec 31, 2021 | 6.08M | 1.51M | 33.05% |
Dec 31, 2020 | 4.57M | - | - |
Dec 31, 2019 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
PetMed Express | 276.97M |
MDxHealth | 75.33M |
Forian | 20.48M |
Jaguar Health | 9.76M |
Barinthus Biotherapeutics | 802.00K |
LVTX News
- 6 weeks ago - LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results - GlobeNewsWire
- 2 months ago - LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223) - GlobeNewsWire
- 3 months ago - LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA® - GlobeNewsWire
- 6 months ago - Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results - GlobeNewsWire
- 8 months ago - LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference - GlobeNewsWire
- 9 months ago - LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results - GlobeNewsWire
- 9 months ago - LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference - GlobeNewsWire
- 11 months ago - LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway - GlobeNewsWire